SCHEMBL4183203

SCHEMBL4183203

COc1ccc2c(O)cc(-c3cnn(CC(C)C)c3)nc2c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.41
FGFR2 P21802 3/20 0.41
FGFR3 P22607 3/20 0.41
FGFR4 P22455 2/20 0.39
KDR P35968 1/20 0.39
MAPK1 P28482 1/20 0.38
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
SYK P43405 1/20 0.36
ABL1 P00519 1/20 0.36
BCR P11274 1/20 0.36
PIM1 P11309 2/20 0.35
PIM3 Q86V86 1/20 0.35
PIM2 Q9P1W9 1/20 0.35
PTGES O14684 1/20 0.35
JAK2 O60674 5/20 0.34
JAK1 P23458 4/20 0.34
TYK2 P29597 4/20 0.34
JAK3 P52333 4/20 0.34
PDK2 Q15119 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4191726 0.90 PRMT5 (0.39) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL4182844 0.88 KDM4E (0.43) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL4177973 0.88 FGFR1 (0.41) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL4178307 0.86 FGFR1 (0.39) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL4178056 0.84 PGK1 (0.46) MAPK1
SCHEMBL13929789 0.82 PLAU (0.45) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL4187139 0.81 FGFR1 (0.45) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL4177971 0.78 PRMT5 (0.39) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL4185266 0.75 KDM4E (0.41) FGFR1FGFR2FGFR3FGFR4KDR
SCHEMBL3627208 0.75 TDO2 (0.51) MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047244-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS I IDENIX PHARMACEUTICALS, INC. (US) 2009-02-19 US disclosed
WO-2009014730-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS IDENIX PHARMACEUTICALS, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047244-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS I SERPINB1, SPINT2, PRSS1 FGFR1 4085/4885FGFR2 4528/4885FGFR3 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.